Scienture Holdings (SCNX)
NASDAQ:SCNX
Want to see SCNX full AI Analyst Report?
Top Page
Scienture Holdings
(NASDAQ:SCNX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.38
▼(-31.45% Downside)
Action:ReiteratedDate:05/02/26
The score is primarily constrained by weak financial performance—severe operating losses and persistent cash burn—alongside a negative/unclear valuation profile due to loss-making results. Technicals are neutral but still reflect a longer-term downtrend, and the recent structured financing introduces additional covenant and repayment-risk pressure.
Positive Factors
Manageable leverage
Recent reporting shows debt is low relative to equity on a TTM basis, which reduces near-term refinancing pressure and interest burden. That improved leverage gives the company more flexibility to support commercialization and R&D spending over the next several months versus prior, more volatile capital structures.
Negative Factors
Persistent cash burn
Operating and free cash flow remain deeply negative on a TTM basis, indicating the business cannot self-fund growth or operations. Persistent cash burn raises reliance on external financing, risks dilution or restrictive financings, and limits the company's ability to invest sustainably in commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
Recent reporting shows debt is low relative to equity on a TTM basis, which reduces near-term refinancing pressure and interest burden. That improved leverage gives the company more flexibility to support commercialization and R&D spending over the next several months versus prior, more volatile capital structures.
Read all positive factors
Scienture Holdings (SCNX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.26M
Dividend YieldN/A
Average Volume (3M)4.08M
Price to Earnings (P/E)―
Beta (1Y)3.36
Revenue Growth-73.18%
EPS Growth92.38%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,630,814
10 Day Avg. Volume11,411,402
30 Day Avg. Volume4,082,790
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)181.35
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-384.13
Enterprise Value/Revenue-15.37K
Enterprise Value/Gross Profit-20.98K
Enterprise Value/Ebitda170.34
Forecast
1Y Price Target
$1.50Price Target Upside172.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scienture Holdings Business Overview & Revenue Model
Company Description
TRxADE HEALTH, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, h...
How the Company Makes Money
null...
Scienture Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 431.61K | 136.64K | 1.36M | 10.25M | 9.89M |
| Gross Profit | -160.30K | 6.00K | 49.03K | 5.52M | 4.75M |
| EBITDA | -38.93M | -17.39M | -6.29M | -1.87M | -5.15M |
| Net Income | -41.51B | 9.07M | -17.84M | -3.47M | -5.32M |
Balance Sheet | |||||
| Total Assets | 84.18B | 104.85M | 12.53M | 3.71M | 5.77M |
| Cash, Cash Equivalents and Short-Term Investments | 6.66B | 308.10K | 314.00 | 1.09M | 3.12M |
| Total Debt | 24.14M | 3.53M | 6.76M | 1.58M | 1.25M |
| Total Liabilities | 14.06B | 25.78M | 11.99M | 3.37M | 2.00M |
| Stockholders Equity | 70.12B | 79.07M | 542.35K | 763.14K | 3.77M |
Cash Flow | |||||
| Free Cash Flow | -13.38B | -14.28M | -2.23M | -1.56M | -2.59M |
| Operating Cash Flow | -13.38B | -14.27M | -2.23M | -1.56M | -2.57M |
| Investing Cash Flow | 0.00 | 27.55M | -275.72K | -427.85K | -22.60K |
| Financing Cash Flow | 19.73B | -12.98M | 1.41M | -35.17K | -208.18K |
Scienture Holdings Technical Analysis
Neutral
0.55
Price Trends
0.41
Negative
0.47
Negative
0.83
Negative
Market Momentum
-0.01
Negative
53.51
Neutral
91.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNX, the sentiment is Neutral. The current price of 0.55 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.41, and below the 200-day MA of 0.83, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 53.51 is Neutral, neither overbought nor oversold. The STOCH value of 91.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SCNX.
Scienture Holdings Risk Analysis
Scienture Holdings disclosed 76 risk factors in its most recent earnings report. Scienture Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scienture Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $17.26M | ― | -44.11% | ― | -73.18% | 92.38% | |
| ― | $8.21M | -0.58 | -8.26% | ― | -28.30% | -86.73% | |
42 Neutral | $8.19M | -0.24 | 336.68% | ― | 63.78% | 82.18% | |
41 Neutral | $4.56M | -0.25 | -112.81% | ― | 18.76% | 84.58% |
* Healthcare Sector Average
SCNX
Scienture Holdings
0.40
-0.52
-56.52%
ZCMD
Zhongchao
1.58
-7.54
-82.68%
HCTI
Healthcare Triangle
2.26
-2,963.33
-99.92%
VSEE
VSee Health
0.18
-0.99
-84.62%
MGRX
Mangoceuticals, Inc.
0.41
-1.34
-76.58%
Scienture Holdings Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Scienture Holdings Secures $11.4 Million Structured Financing Deal
Negative
May 1, 2026
On April 27, 2026, Scienture Holdings, Inc. entered into and closed a financing deal with Streeterville Capital, LLC, issuing two secured promissory notes totaling $11.42 million, with $8 million delivered at closing and $3 million placed in a con...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.